Together With COTI-2 and COTI-219, the Company Is Building a Compelling Pipeline of Novel, Oral, Small Molecules Targeting Previously "Undruggable" Cancer Targets
LONDON, ON and BOSTON, MA--(Marketwired - October 14, 2016) - Critical Outcome Technologies Inc. ("COTI" or the "Company") (TSX VENTURE: COT) (OTCQB: COTQF), announced today that its Chief Executive Officer, Dr. Wayne Danter, and President, Ms. Alison Silva, provided a summary of the key milestones achieved during the past year and highlighted the Company's strategic objectives moving forward at the Company's Annual General and Special Meeting of Shareholders ("AGM") held on Thursday, October 13, 2016.
Highlights of the presentation included:
A copy of the full slide presentation can be found on COTI's website at: http://criticaloutcome.com/investors/events or at www.Slideshare.net/CriticalOutcome.
Other highlights of the AGM included:
About Critical Outcome Technologies Inc. (COTI)
COTI is a clinical stage biotechnology company advancing innovative and targeted therapies for the treatment of cancer. The Company's lead compound, COTI‐2, has a novel p53‐dependent mechanism of action with selective and potent anti‐cancer activity. COTI‐2 is being initially evaluated for the treatment of gynecologic cancers, which includes ovarian, cervical, and endometrial cancers in a Phase 1 clinical trial at the MD Anderson Cancer Center at the University of Texas and the Lurie Cancer Center at Northwestern University. The Company has secured orphan drug status in the U.S. for COTI‐2 for the treatment of ovarian cancer in patients failing first line therapies and is planning additional studies in other cancer indications such as head and neck, Li‐Fraumeni Syndrome, and acute myelogenous leukemia. These studies are supported by more than ten animal xenograft models showing both single and combination agent activity of COTI‐2 with other leading cancer drugs. Preclinical data provides evidence to suggest a potentially dramatic change in the treatment of cancers with mutations of the p53 gene.
Follow @CriticalOutcome on Twitter at http://twitter.com/CriticalOutcome
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information, visit www.criticaloutcome.com or contact:
Critical Outcome Technologies Inc.
Dr. Wayne Danter
Chief Executive Officer
Tel: 519-858-5157
Email: [email protected]
Alison Silva
President
Tel: 860-798-0816
Email: [email protected]